Associate-Director Flow and Image Cytometry Roswell Park ComprehensiveCancer Center

目前的申请寻求继续工资支持汉斯明德曼，博士谁服务 作为流式细胞仪和图像细胞仪共享资源（FICSR）的副主任， 罗斯威尔公园综合癌症中心（Roswell Park Comprehensive Cancer Center）该职位于2007年设立 监督各种成像（共聚焦，活细胞成像）和流动的研究应用 细胞仪平台，并在这些领域应用他的丰富经验 与FICSR研究者用户群进行合作和协商。拥有超过35年的 具有流式细胞术和图像细胞术的临床和研究应用经验（在Roswell工作30年 Minderman博士在他的职业生涯中与许多研究人员合作， 癌症中心的NIH资助项目。FICSR是罗斯韦尔公园癌症的一个组成部分 癌症中心主任约翰逊博士提供的中心支持补助金（P30 CA 016056） 作为首席研究员。肿瘤免疫学和免疫治疗（TII）CCSG计划， 以前由单位主任共同领导的原始应用程序，Odunsi博士，是主要用户 FICSR的基础;但许多NIH资助的研究人员在所有5个CCSG计划积极 根据PAR 21-286的目的，与Minderman博士合作并协商 融资机会。在他的第一个R50任期（2016-2021），明德曼博士的贡献， 罗斯韦尔公园研究企业一直是重要的和有影响力的，特别是在 NIH资助的研究。截至2021年10月，137个校外资助申请依赖于 在FICSR被授予罗斯韦尔公园教师，59人被NIH授予，其中22人 TII计划的成员。癌症中心还在癌症治疗方面进行了大量投资。 FICSR与收购一个新的共聚焦显微镜，两个光谱流式细胞仪分析仪 和第三台Fortessa分析仪随着R50计划的变化， 实验室（PAR-20-288）和核心（PAR-20-287）科学家之间以及FICSR 作为Roswell Park CCSG基础设施的组成部分，约翰逊博士作为 CCSG赠款，现在将担任该股主任的续期申请。

The current application seeks continued salary support for Hans Minderman, PhD who serves as the Associate Director of the Flow and Image Cytometry Shared Resource (FICSR) of the Roswell Park Comprehensive Cancer Center (Roswell Park). This position was created in 2007 to oversee the research applications of the various imaging (confocal, live cell imaging) and flow cytometry platforms available in the facility and to apply his extensive experience in these areas in collaborations and consultations with the FICSR investigator user base. With over 35 years of experience in clinical and research applications of flow and image cytometry (30 years at Roswell Park), Dr Minderman throughout his career has collaborated with many investigators at the Cancer Center on NIH funded projects. The FICSR is an integral part of Roswell Park’s Cancer Center Support grant (P30CA016056) for which the cancer center Director, Dr Johnson serves as the Principal Investigator. The Tumor Immunology & Immunotherapy (TII) CCSG program, previously co-led by the Unit Director on the original application, Dr Odunsi, is the major user base of the FICSR; but numerous NIH-funded researchers across all 5 CCSG programs actively collaborate and consult with Dr Minderman commensurate with the purpose of the PAR 21-286 funding opportunity. During his first R50 tenure (2016-2021), Dr Minderman’s contributions to Roswell Parks research enterprise have been significant and impactful specifically with regards to the NIH-funded research. As of October 2021, 137 extramural grant applications dependent on FICSR were awarded to Roswell Park faculty, 59 were awarded by NIH, 22 of which to members of the TII program. The cancer center has also made significant investments in the FICSR with the acquisition of a new confocal microscope, two spectral flow cytometry analyzers and a 3rd Fortessa analyzer. With the changes in the R50 program now making the distinction between Laboratory (PAR-20-288)- and Core (PAR-20-287)-based scientists and with the FICSR being an integral part of the Roswell Park CCSG infrastructure, Dr Johnson as the PI of the CCSG grant, will now serve as the Unit Director for the renewal application.